Key points are not available for this paper at this time.
TAT using 211AtPSMA5 resulted in excellent tumor growth suppression with minimal side effects in the normal organs. 211AtPSMA5 should be considered a new possible TAT for metastatic CRPC, and translational prospective trials are warranted.
Watabe et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: